{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:18:38Z","timestamp":1778275118194,"version":"3.51.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,16]]},"DOI":"10.7759\/cureus.105345","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:42:21Z","timestamp":1773715341000},"source":"Crossref","is-referenced-by-count":1,"title":["Erythema Multiforme Associated With Pembrolizumab Treatment for Recurrent Urothelial Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Carolina","family":"Ledesma-F\u00e9lix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"Vald\u00e9s-Loperena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda E","family":"M\u00e1rquez-Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Gatica-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio E","family":"Leal-Osuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin Q","year":"2023","unstructured":"Yin Q, Wu L, Han L, et al.. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023, 14:1167975. 10.3389\/fimmu.2023.1167975","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.08.030","article-title":"Adverse dermatologic reactions in patients treated with immune checkpoint inhibitors (article in Spanish)","volume":"114","author":"Fayos Gregori R","year":"2023","unstructured":"Fayos Gregori R, Labrandero Hoyos C, Pe\u00f1uelas Leal R, Alegre de Miquel V. Adverse dermatologic reactions in patients treated with immune checkpoint inhibitors (article in Spanish). Actas Dermosifiliogr. 2023, 114:T288-9. 10.1016\/j.ad.2022.08.030","journal-title":"Actas Dermosifiliogr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo M","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, et al.. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015, 151:1206-12. 10.1001\/jamadermatol.2015.1916","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.08.021","article-title":"Erythema multiforme associated with the immune checkpoint inhibitors: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System","volume":"91","author":"Godfrey H","year":"2024","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Erythema multiforme associated with the immune checkpoint inhibitors: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. J Am Acad Dermatol. 2024, 91:1233-4. 10.1016\/j.jaad.2024.08.021","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt J","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al.. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017, 376:1015-26. 10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"ref6","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2026","author":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)","year":"2025","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Management of Immunotherapy-Related Toxicities, Version 1.2026. National Comprehensive Cancer Network (NCCN), 2025."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study","volume":"88","author":"Zhang S","year":"2023","unstructured":"Zhang S, Tang K, Wan G, et al.. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study. J Am Acad Dermatol. 2023, 88:1024-32. 10.1016\/j.jaad.2022.12.048","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin S","year":"2022","unstructured":"Wongvibulsin S, Pahalyants V, Kalinich M, et al.. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol. 2022, 86:563-72. 10.1016\/j.jaad.2021.03.094","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000545623","article-title":"Adverse cutaneous reactions to monoclonal antibodies: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and fixed drug eruption - a systematic review","volume":"10","author":"Kherallah K","year":"2025","unstructured":"Kherallah K, Ahmad I, Bandara A, Kattoula J, Rodriguez I, Worswick S. Adverse cutaneous reactions to monoclonal antibodies: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and fixed drug eruption - a systematic review. Biomed Hub. 2025, 10:105-15. 10.1159\/000545623","journal-title":"Biomed Hub"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2025.2512264","article-title":"Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review","volume":"2025","author":"Silvi G","year":"2025","unstructured":"Silvi G, Rosi E, Scandagli I, Di Cesare A, Prignano F. Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review. J Chemother. 2025, 2025:1-5. 10.1080\/1120009X.2025.2512264","journal-title":"J Chemother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452549-erythema-multiforme-associated-with-pembrolizumab-treatment-for-recurrent-urothelial-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:42:23Z","timestamp":1773715343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452549-erythema-multiforme-associated-with-pembrolizumab-treatment-for-recurrent-urothelial-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.105345","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}